Skip to main content

STAT reports that an expert has warned obesity drugs based on GLP-1 may become the next major dispute over access to medicines in lower-income countries. The source points to concerns about how these new treatments will be distributed and priced outside wealthier markets.

This issue matters for pharma and healthcare leaders, as drug access and pricing are under increasing scrutiny from policymakers and the public. Companies may need to consider how their global strategies affect both reputation and regulatory risk.

STAT reports that the FDA has created a new regulatory category for the supplement NAC, which has long been available but operated in a legal gray area. The decision follows advocacy from MAHA and is seen as a shift in how supplements may be regulated in the future.

This matters for pharma and biotech executives because regulatory clarity can affect compliance, market access, and future product strategies. The move may signal further changes in supplement oversight, making it important for regulated firms to track similar developments.

A new Trump administration regulation aims to address fraud, with all of the anticipated savings expected to come from Medicare Advantage, according to STAT. The regulation is intended to target so-called 'fraudsters' in the programme, which is a major part of the US health insurance market.

This move signals increased regulatory attention on Medicare Advantage, which may affect how health insurers and providers manage billing and compliance. Senior executives in health insurance and healthcare should review their risk controls and prepare for possible audits or reimbursement changes.

Apple has announced a new study, in partnership with clinical AI platform OpenEvidence, to evaluate the usefulness of conversational AI health tools. The Apple Health AI Usage Study will use a dedicated iOS app where up to 200,000 US adults can ask health questions and rate the AI-generated answers for accuracy, detail, and relevance. The app, which is now available, requires an iPhone 15 Pro running iOS 26 or later and does not use Apple Intelligence or integrate with Siri.

Participants can choose to share Apple HealthKit data, such as activity, sleep, or lab results, to give more context for the app’s responses. Apple says privacy is a priority and that collected data will not be used to train AI models. The study aims to improve the design and reliability of AI-powered health tools, making them easier for users to understand and act on.

For regulated healthcare organisations, the study’s scale and focus on user-rated accuracy highlight the growing emphasis on clinical rigour and privacy in digital health. The findings may influence how AI is adopted and regulated in patient-facing applications. Senior executives should monitor how Apple’s approach to user engagement and data privacy sets expectations for future health AI tools.

STAT reports that Biogen is preparing to announce results from a pivotal clinical trial of its experimental lupus therapy. The readout is expected soon, according to the source.

This matters for senior pharma and biotech executives because the trial outcome could influence development strategies, portfolio priorities and market competition in autoimmune disease. The results may also affect future investment and partnership opportunities in the lupus space.

NHS England has removed a statement from its website that said 137 hospital trusts were benefiting from Palantir’s AI-powered health data platform, after The Guardian found that 29 trusts were not using all or most of the technology. The original claim was challenged when trusts confirmed, via freedom of information requests, that the system was either not live or not in use at their sites. The Office for Statistics Regulation is now reviewing the NHS’s claims about the system’s reach and impact.

The Palantir contract, worth £330m, is under scrutiny as ministers consider whether to extend it to 2029. Critics, including MPs, unions and campaign groups, argue that the effectiveness of Palantir’s technology has been overstated and that its presence raises security and sovereignty concerns. NHS England was previously warned by the statistics regulator about unsupported claims regarding extra operations attributed to the platform.

The debate comes amid lobbying by Palantir and calls from campaigners and some MPs to develop an open, UK-based health data platform instead. Several groups have urged the government to end the Palantir contract by 2027, using a transition period to move to alternative solutions. The dispute highlights the importance of accurate reporting and independent oversight in large-scale health data projects.

STAT says new documents have raised further questions about Medicare’s AI prior-authorisation experiment. The article points to ongoing scrutiny of how artificial intelligence is being used in healthcare authorisation processes.

This matters for healthcare executives and insurers as it signals persistent regulatory and operational uncertainty. The results may affect future adoption of AI in clinical settings and how authorisation decisions are made.

Pfizer spent up to $10 billion to acquire Metsera last year, according to STAT. The company is now involving private equity firm Blackstone to help finance the deal, reflecting a trend of outside investors entering major pharmaceutical transactions.

This partnership signals the increasing appeal of obesity treatments to both pharma companies and private equity. For senior executives, the deal points to new financing models and rising competition in a high-growth therapeutic area. Further deals involving private equity could follow as the sector evolves.

STAT reports that the FDA has ended the fast-track drug review initiative started in June 2025 under former Commissioner Marty Makary. No further details on the reasons or next steps were provided.

This decision could slow approval processes for new drugs, which matters for pharma and biotech executives managing regulatory risk and market entry. Companies should monitor for further guidance from the FDA.

PHI Health, a national air ambulance provider, is suing employers across the US for unpaid out-of-network medical helicopter bills, with individual claims reaching nearly $27,000. The lawsuits target both small businesses and large corporations, as well as public sector entities and nonprofits, according to STAT. Previously, providers sought payment from insurers, but are now increasingly pursuing employers directly after winning arbitration awards under the No Surprises Act.

The 2022 No Surprises Act was intended to protect patients from unexpected medical bills, but its arbitration process has led to higher payments for out-of-network providers. Georgetown University researchers estimate this has added around $20 billion in extra costs to the health care system, much of which is passed on to employers and workers through higher premiums. PHI Health has filed lawsuits against hundreds of companies, sometimes naming unknown defendants as placeholders if the plan sponsor is unclear.

Legal experts say this tactic shifts the financial burden from insurers to the employers who sponsor health plans, undermining claims that insurers are solely responsible for payment delays. The litigation adds complexity and risk for organisations managing employee health benefits, with the potential for further escalation as more providers adopt this approach.